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ObesityMetabolic syndrome is a constellation of multiplemetabolic risk factors including abdominal obesity, glucose in-
tolerance, insulin resistance, dyslipidemia and hypertension. Over the past decades, the prevalence of metabolic
syndrome has increased dramatically, imposing a devastating, pandemic health threat. More importantly, individ-
uals withmetabolic syndrome are at an increased risk of diabetes mellitus and overall cardiovascular diseases. One
of the common comorbidities of metabolic syndrome is heart anomalies leading to the loss of cardiomyocytes, car-
diac dysfunction andultimately heart failure. Up-to-date, a plethora of cell signaling pathways have beenpostulated
for the pathogenesis of cardiac complications in obesity including lipotoxicity, inﬂammation, oxidative stress, apo-
ptosis and sympathetic overactivation although the precise mechanism of action underscoring obesity-associated
heart dysfunction remains elusive. Recent evidence has indicated a potential role of protein quality control in
components of metabolic syndrome.Within the protein quality control system, the autophagy–lysosome pathway
is an evolutionarily conservedpathway responsible for bulkdegradation of large intracellular organelles andprotein
aggregates. Autophagy has been demonstrated to play an indispensible role in themaintenance of cardiac geometry
and function under both physiological and pathological conditions. Accumulating studies have demonstrated that
autophagy plays a pivotal role in the etiology of cardiac anomalies under obesity and metabolic syndrome. In this
minireview, wewill discuss on how autophagy is involved in the regulation of cardiac function in obesity andmet-
abolic syndrome. This article is part of a Special Issue entitled: Autophagy and protein quality control in cardiomet-
abolic diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Metabolic syndrome (MetS), previously termed as Syndrome X,
was originally deﬁned as a constellation of devastatingmetabolic dis-
turbances, including hyperglycemia, dyslipidemia and hypertension.
Subsequent experimental, clinical and epidemiological studies demon-
strated that abdominal obesity is also closely associatedwith the etiology
of metabolic syndrome [1]. Although a number of health organizations
including the World Health Organization (WHO), the National Health
and Nutrition Examination (NHANES), the European Group for the
Study of Insulin Resistance and the National Cholesterol Education
Program's Adult Treatment Panel III (NCEP: ATPIII), have somewhat dis-
parate deﬁnitions formetabolic syndrome, the essential core components
for metabolic syndrome are reminiscent namely central obesity, glucose
intolerance, insulin resistance, dyslipidemia and hypertension [2–5].
Over the last decades, the rate of metabolic syndrome-caused death
rose dramatically in the United States and other parts of the world. Data
from the NHANES III Survey (1998–1994) suggested that the unadjusted
prevalence and age-adjusted prevalence of metabolic syndrome asy and protein quality control in
1 307 766 2953.deﬁned by ATP (Adult Treatment Panel) III were 21.8% and 23.7%, respec-
tively, in the United States [6]. In the following 5 years, a signiﬁcant in-
crease was observed in the prevalence of metabolic syndrome in the
United States. According to the report from NHANES 1999–2000, the un-
adjusted prevalence and age-adjusted prevalence ofmetabolic syndrome
were increased to 26.7% and 27%, respectively [7]. Interestingly, the prev-
alence ofmetabolic syndrome is found to behighly age-dependent. Based
on the data from NHANES III survey, the prevalence of metabolic syn-
drome was only 6.7% among participants aged 20–29 years. However,
more than 40% of participants aged 60 or abovewere found to be afﬂicted
with metabolic syndrome [6]. The total population of adults suffering
from metabolic syndrome increased dramatically from ~41 million in
1990 to 55 million in 2000 [7]. Considering that obesity (one of the
core components of metabolic syndrome) is rapidly approaching an
epidemic proportion in the United States, there is an alarming high prev-
alence of metabolic syndrome in Americans. The prevalence of being
overweight or obese among US adults is around 68.2% in 2010, affecting
154.7 million of the US adults [8]. In particular, there has been a dramatic
increase in overweight children and adolescents. For example, in the
NHANES from 1999 to 2002, 31% of children and adolescents aged 6 to
19 years were at risk of being overweight or obese. This trend continues
to rise resulting in 16.9% of US children being afﬂicted with obesity in
2010 [8]. Not surprisingly, the prevalence ofmetabolic syndromewas sig-
niﬁcantly higher in severely obese young individuals [body mass index
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metabolic disturbances (all of which are well documented candidates
for cardiovascular diseases) it is not unexpected that it can induce cardiac
injury and dysfunction [11,12]. Although it is extensively studied, the
mechanisms underlying the development of cardiac injury under meta-
bolic syndrome still remain elusive [5,13].
Autophagy (from the Greek auto, meaning ‘self’, and phagy, meaning
‘to eat’) is an evolutionarily conserved pathway for bulk degradation of
large intracellular organelles and protein aggregates [14]. It is a highly dy-
namic process, characterized by the formation of a double-membrane
vacuole (autophagosome). After fusing with lysosomes, the inner mem-
brane and the engulfed components of the autophagosome are degraded
by lysosome, forming a single-membrane vacuole structure called
autophagolysosome/autolysosome [13]. It is widely accepted that basal
autophagy possesses an indispensible role in the maintenance of cardiac
geometry and function under physiological conditions [15–17]. However,
cardiac autophagy is susceptible to various cardiovascular insults such as
ischemia–reperfusion injury [18], pressure overload [19], and certain
cardiotoxic drugs including doxorubicin [20]. Interestingly, accumulating
evidence suggests that disturbed autophagy is involved in the onset and
development of cardiac injuries in metabolic syndrome [11,12,21,22].
However, disparate results have been noted for autophagy in the heart
depending upon the state of metabolic syndrome [11,12,21,22]. For
example, one study reported that cardiac autophagy initiation was
suppressed in atherogenic diet-induced obesity, insulin resistance and
dyslipidemia [11]; another two studies showed that myocardial
autophagy was unaffected in high fat diet-induced obesity, insulin
resistance and dyslipidemia [21,22]; our studies indicated that myocar-
dial autophagosomematuration was disrupted in high fat diet-induced
obesity, glucose resistance, insulin resistance and dyslipidemia [12].
2. Metabolic syndrome and cardiac anomalies
Since metabolic syndrome is a concurrence of independent risk
factors for cardiovascular disease, it is not surprising that individuals
with metabolic syndrome are found to bemore susceptible for heart in-
jury and contractile dysfunction [23,24]. According to the data from the
Botnia clinical study involving Finnish and Swedish participants, the
presence of metabolic syndrome dramatically increased morbidity and
mortality of cardiovascular disease in these participants [25]. At the
same time, a tight association ofmetabolic syndromewith cardiovascular
and the overall mortality was unveiled by an independent clinical study
involving middle-aged Finnish men [23]. More importantly, their results
demonstrated that cardiovascular disease and all-cause mortality are
signiﬁcantly increased in middle-aged men suffering from metabolic
syndrome, even without any baseline cardiovascular diseases [23]. The
propensity of cardiovascular disease in metabolic syndromewas also ex-
tensively studied in an American population in the San Antonio Heart
Study (SAHS) [26]. Based on data obtained from SAHS, 156 out of 2570
participants with metabolic syndrome experienced a cardiovascular
event within a time frame of 7.5 years. The overall sensitivity or propen-
sity for predicting cardiovascular disease inmetabolic syndromewas 67%
[26]. More importantly, accumulating studies have shown that metabolic
syndrome is tightly associated with the development of abnormal left
ventricular geometry and function [27,28]. Using echocardiography,
Japanese descendants with metabolic syndrome displayed left ventricu-
lar diastolic dysfunction independent of left ventricularmass and systolic
function [29]. Along the same line, compromised left ventricular systolic
and diastolic functionswere observed in Chinese patients withmetabolic
syndrome as determined by strain and strain rate imaging [30]. More in-
terestingly, recent studies suggest that metabolic syndrome-associated
abnormal left ventricular structure and function are independent of levels
of blood pressure and fasting plasma glucose [31], although it is closely
tied with epicardial adiposity [27].
In line with the clinical observations in patients withmetabolic syn-
drome, results from experimental models of metabolic syndrome alsoconﬁrmed unfavorable changes in cardiac geometry and function in
metabolic syndrome [11,12,32,33]. Among the various experimental
models, diet-induced obesity and metabolic syndrome are deemed a
widely accepted model to evaluate metabolic syndrome-associated
cardiac anomalies [11,12]. For example, prolonged (5-month) intake
of 45% high fat diet induced metabolic syndrome in a mouse model, as
evidenced by obesity, glucose intolerance, insulin resistance and
dyslipidemia [12,32,33]. In particular, high fat diet-induced metabolic
syndrome dramatically altered cardiac geometry and function, as evi-
denced by decreased fractional shortening and increased ventricular
wall thickness, and left ventricular end diastolic and systolic diameters
(LVEDD, LVESD) [12,32,33]. Meanwhile, cardiomyocyte contractile func-
tion is also remarkably impaired in murine models of high fat diet-
inducedmetabolic syndrome, as evidencedbydecreased peak shortening
and maximal velocity, and increased time-to-90% relengthening [12,32,
33]. These changes in cardiac geometry and function are accompanied
with overt interstitial ﬁbrosis and ultrastructural changes following
chronic high fat diet feeding [12,33]. In a metabolic syndrome-prone
Ossabaw swine model, atherogenic diet was employed to induce meta-
bolic syndrome [11]. Ossabaw pigs developed metabolic syndrome
following a 14-week atherogenic diet intake. Although cardiac output
and myocardial perfusion increased in these Ossabaw pigs with meta-
bolic syndrome, they displayed myocardial hypoxia associated with in-
creased inﬂammation, oxidative stress, mitochondrial dysfunction as
well as ﬁbrosis [11].
3. Protein quality from autophagy
In eukaryotic cells, there are twomajor proteolytic systemsmediating
protein degradation and recycling namely the ubiquitin–proteasome and
the autophagy–lysosome pathways. Unlike the ubiquitin–proteasome
pathway, the autophagy–lysosome pathway is governing bulk degrada-
tion of large cytoplasmic organelles and protein aggregates that cannot
be degraded by the proteasome system [34]. As an evolutionarily con-
served pathway, autophagy pathway is a highly dynamic process with a
step-wise process [12,13]. The hallmark of autophagy is the formation
of autophagosome, a double-membrane vacuole in which subcellular
cargos are sequestered for degradation [12,13]. After being fused with
lysosome, the inner membrane of autophagosome is degraded from a
singlemembrane structure named as autophagolysosome/autolysosome.
Within the autophagolysosome, the engulfed proteins and cytoplasmic
organelles are degraded by enzymes in the lysosome. Subsequently,
free amino acids and fatty acids are generated and released from
autophagolysosomes to facilitate cell survival under various stresses,
such as starvation [35].
According to the mode of cargo delivery to the lysosome and the
selectivity of the system, three different forms of autophagy have been
deﬁned: (i) chaperone-mediated autophagy (CMA); (ii) micro-
autophagy; and (iii) macroautophagy [13]. CMA is a lysosomal pathway
of proteolysis that is mediated by certain molecular chaperones in the
cytosol and in the lysosomal lumen [36]. Both microautophagy and
macroautophagy sequestrate and degrade large structures in either a
selective or non-selective manner. Macroautophagy, hereafter referred
to as autophagy, is the one that is extensively studied and the best un-
derstood [12,19,20,35]. According to the selectivity of the target cargo
for degradation, autophagy can be further speciﬁed into mitophagy
(mitochondria), ribophagy (ribosomes), pexophagy (peroxisomes),
lipophagy (lipids), and reticulopathy (endoplasmic reticulum) to
denote speciﬁc target for autophagy [19,37].
3.1. Regulation of autophagy
The autophagy pathway is tightly regulated by various molecules,
especially the Atg (AuTophaGy-related gene) family and mammalian
target of rapamycin (mTOR) kinase. The Atg family members were
ﬁrst discovered in yeast and many of them have orthologues in
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identiﬁed with an essential regulatory role in autophagy. The proteins
encoded by these genes are involved in the regulation of the entire
autophagy process, from the nucleation of autophagic vacuoles to the
formation of the autophagosomes and autophagolysosomes [38].
In addition to these Atg proteins, another pivotal player in the regula-
tion of autophagy pathway ismTOR, a kinase regulating protein synthesis
and cell growth in response to growth factors, nutrients, energy levels,
and stress [39]. Accumulating studies have suggested that mTOR plays
an important role in the negative regulation of autophagy [14]. According
to the proteins bonded, mTOR complex is divided into two forms, mTOR
complex 1 (mTORC1) and mTOR complex 2 (mTORC2) [40]. mTOC1,
consisting of mTOR, raptor and mLST8, is rapamycin-sensitive. mTOC2,
containing mTOR, rictor, mLST8, PRAS40, and DEPTOR, is rapamycin-
insensitive [40]. Through phosphorylating Ulk1 (the ortholog of mam-
malian Atg1), mTOR forms a complex with phosphorylated Ulk1,
Atg13 and FIP200, thus inhibiting autophagy [40]. Through inhibition
of mTOC1, rapamycin is widely employed to induce autophagy [41,42].
On the other hand,mTOR is tightly regulated by its upstream regula-
tor, Ras homology enriched in brain (Rheb). It is believed that Rheb
physically binds with mTOR, leading to its activation [43]. At the same
time, Rheb is negatively regulated by tuberous sclerosis complex
(TSC). TSC is composed of tuberous sclerosis complex 1 (TSC1) and
tuberous sclerosis complex 2 (TSC2), where TSC1 is the regulatory com-
ponent and TSC2 is the catalytic component [43]. Two well-established
regulatorswere present upstream of TSC namely Akt and AMPK. The ac-
tivity of TSC2 is inhibited by PI3K–Akt primarily through phosphoryla-
tion and membrane partitioning [43,44]. In contrast to Akt, AMPK can
activate autophagy indirectly by regulating the activity of mTOR.
Activated AMPK phosphorylates and activates TSC2, leading to Rheb in-
hibition and mTORC1 suppression (Scheme 1) [43].
3.2. Regulation of autophagic ﬂux
Since autophagy is a highly dynamic and step-wise process, evaluation
of its status based merely on level of Atg members might not be reliable
[14]. Traditionalmethods to evaluate autophagy status includemeasuringScheme1. Schematic diagramdepicting the sequential cellular andmolecular aspects of autophag
highly dynamic process that occurs in a step-wisemanner. Red arrows and black lines represent a
as Protein Kinase B (PKB); MetS, Metabolic Syndrome; mTOR, mammalian target of rapamycin; R
51-like kinase 1.the expression of Atg proteins including Beclin1, LC3B II or the ratio LC3B
II/LC3B I, or usingmicroscopy tomonitor the number of autophagosomes.
However, an increase in the number of autophagosomes does not neces-
sarily reﬂect the activation of autophagy [12,20,45]. On the one hand, the
increase of autophagosomesmight indicate that the autophagy is activat-
ed [35,42]. On the other hand, it could be the result of decreased degrada-
tion by lysosomes [12,20,46]. Therefore, the concept of ‘autophagic ﬂux’ is
introduced to better reﬂect the dynamic process of autophagy (Scheme1)
[47].
To better evaluate the status of autophagic ﬂux, several assays have
now been developed. One of the two commonly employed techniques
for the evaluation of autophagic ﬂux in vivo is to assess the number of
autophagosomes and the accumulation of its selective substrates. The
best studied speciﬁc substrate for autophagic degradation is p62/
sequestosome 1 (SQSTM) [41]. Since LC3B II is an autophagy marker
on themembrane of autophagolysosomes andp62 is selectively degrad-
ed by autophagolysosomes, total levels of p62 are inversely correlated
with the ‘authentic’ autophagic activity. Therefore, an increase of LC3B
II in combinationwith a decrease in p62 indicates autophagic ﬂux activa-
tion, while an accumulation of both LC3B II and p62 denotes interruption
of autophagic ﬂux [12,20,45]. Another widely adoptedmethod to discern
autophagy induction from suppressed autophagosome degradation
in vivo is to manually inhibit the fusion between autophagosomes with
lysosomes or lysosome enzyme activity [14]. Inhibiting the degradation
of autophagosomes induces the accumulation of autophagosomes that
should be degraded by lysosomes [14]. Accordingly, the difference
between the amount of LC3B II detected in the presence or absence of
lysosomal inhibitors reﬂects the amount of LC3B II degraded by
autophagolysosomes [14,20,45]. The LC3B II turnover assay has been
used to evaluate changes in autophagic ﬂux in murine hearts in vitro
and in vivo [20,45]. In in vitro studies, the formation of autophagosomes
and autophagolysosomes can be monitored by ﬂuorescence microscopy
[45]. This is based on the difference in pH value between auto-
phagosomes and autophagolysosomes. The pH is lower in auto-
phagolysosomes than in autophagosomes, which, in turn, can quench
the ﬂuorescent signal of green ﬂuorescent protein (GFP) but not red ﬂuo-
rescent protein (RFP) [45]. Following transfection with monomeric (m)y and autophagicﬂux affected in theheart undermetabolic syndrome (MetS). Autophagy is a
ctivation and inhibition, respectively. AMPK, AMP-activated protein kinase; Akt: also known
heb, Ras homology enriched in brain; TSC, tuberous sclerosis complex; Ulk1, uncoordinated
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with yellow ﬂuorescence and red ﬂuorescence, respectively. By assessing
the number of yellow and red dots, the formation of autophagosomes
and autophagolysosomes can be distinguished for the assessment of
autophagic ﬂux [45].
3.3. Autophagy and metabolic syndrome-associated cardiac anomalies
The pivotal role of autophagy in the maintenance of cardiac struc-
ture and function has been extensively studied over the past years. It
is widely conceived that basal levels of autophagy in physiological con-
ditions are indispensable for cell survival [16]. However, it still remains
controversial with regard to the precise role of autophagy in themainte-
nance of cardiac homeostasis under pathological conditions, especially
cardiac hypertrophy and heart failure [19,20,48,49]. Although the corre-
lation between metabolic syndrome and cardiac injury has been exten-
sively documented [5,25,29–31], the role of autophagy in metabolic
syndrome-induced cardiac anomalies has not been fully appreciated
until recently [11,12,21,22]. To add to the complexity, the current avail-
able data of cardiac autophagy in metabolic syndrome appears to be
rather conﬂicting with unchanged [21,22] and decreased autophagy
[11], as well as disrupted autophagic ﬂux [12].
The ﬁrst study describing cardiac autophagy in metabolic syndrome
was evaluated in an atherogenic diet-inducedOssabaw swinemetabolic
syndrome model [11] (Table 1). Metabolic syndrome-prone Ossabaw
pigs were fed an atherogenic diet 10 weeks to induce obesity and
14 weeks to induce metabolic syndrome (obesity, dyslipidemia, and in-
sulin resistance). Ten-week atherogenic diet feeding induced ventricular
dysfunction with preserved cardiac output. In contrast, 14-week feeding
increased cardiac output but loweredmyocardial perfusion. Their data on
myocardial autophagy in obesity andmetabolic syndrome are conﬂicting.
In the state of obesity, the protein level of cardiac Atg5 was signiﬁcantly
increased, while other autophagy markers did not show any signiﬁcant
changes. However, in the state of metabolic syndrome, myocardium
displayed increased protein levels of Atg5 but decreased ULK1, Beclin1
and the LC3B II/I ratio (Scheme 1). Although the authors claimed that
myocardial autophagy was suppressed in the swine model of metabolic
syndrome, their data were in conﬂict with their statement, especially
with the increased expression of Atg5 protein. Furthermore, the autoph-
agic ﬂux was not evaluated in this study. The decrease of autophagyTable 1
Evaluation for the role of myocardial autophagy under metabolic stress.
Changes in cardiac autophagy Metabolic disorder model
Activated mTOR;
inhibited autophagy
60% high fat diet-induced obesity in
mice with glucose intolerance
Inhibited autophagy
Inhibited AMPK, activated;
decreased LC3B II/I with
unchanged Beclin1
45% high fat diet-induced obesity in
mice with glucose intolerance
Inhibited AMPK, activated Akt–mTOR,
disrupted autophagic ﬂux
45% high fat diet-induced metabolic
syndrome in mice
(obesity, glucose intolerance, insulin resistance)
Increased Atg5, decreased Ulk1,
Beclin1, and LC3B II/I
Atherogenic diet-induced metabolic syndrome
in Ossabaw pigs (obesity, insulin resistance, dyslipide
Unchanged AMPK, decreased
LC3B II/I
58% high fat diet induced metabolic syndrome
(obesity insulin resistance, dyslipidemia)
Unchanged LC3B II/I and Atg5 60% high fat diet-induced metabolic syndrome in
female mice (obesity, insulin resistance,
glucose intolerance)
Increased myocardial LC3B II/I 60% high fructose diet-induced insulin resistance
Decreased AMPK and LC3B II/I Diabetic OVE26 mice
Inhibited autophagic ﬂux STZ-induced type 1 diabetes mellitusmarkers, including LC3B II and Beclin1, does not necessarily support the
notion of autophagy suppression. It might be explained as the result of
autophagy induction [14]. Further studies are required to differentiate
autophagy suppression from induction in this Ossabaw swine model of
metabolic syndrome. At the same time, metabolic syndrome-induced
cardiac anomalies and myocardial autophagy change were examined in
amousemodel [22] (Table 1). After 12 weeks of 60%high fat diet feeding,
the seventeen-week-old female mice developed metabolic syndrome, as
evidenced by obesity, hyperglycemia, hyperinsulinemia and dyslipid-
emia. In these female mice with metabolic syndrome, cardiac function
was suppressed. However, autophagy was unaffected in these mice
with metabolic syndrome, as evidenced by the ratio of LC3B II/I and
mRNA expression of Atg5. Interestingly, treatment with a carbon
monoxide-releasing molecule (CORM-3) increasedmyocardial autoph-
agy and attenuated cardiac dysfunction without affecting metabolic
syndrome. Furthermore, the cardioprotective effect of CORM-3 was
dependent on autophagy activation as autophagy inhibition by 3-
methyladenine nulliﬁed the beneﬁcial effect of CORM-3 [22]. The effect
ofmetabolic syndrome onmyocardial autophagywas also reported by a
follow-up study [21] (Table 1). Here, 6-week-old male C57 mice were
fed 58% high fat diet for ten weeks to induce metabolic syndrome, in-
cluding obesity, insulin resistance and dyslipidemia. Caloric restriction
was found to improve high fat diet-induced metabolic syndrome, the
effects of which were associated with myocardial autophagy enhance-
ment [21].
To better understand the cardiac autophagy in metabolic syndrome
and associated cardiac injury, a high fat diet-induced murine model of
metabolic syndrome and obesity was employed in the laboratory
setting [12] (Table 1). Mice were fed a 45% high fat diet for 20 weeks
to inducemetabolic syndrome, as evidenced by obesity, glucose intoler-
ance, dyslipidemia, and insulin resistance. These high fat fed mice
displayed reduced cardiac output and fractional shortening along with
compromised cardiomyocyte contractile function and intracellular
Ca2+ handling. Interestingly, our data suggested possibly activated
cardiac autophagy in mice with metabolic syndrome, as evidenced by
increased levels of both LC3B I and LC3B II. To further discern contribu-
tion of autophagy induction versus suppressed autophagosome degra-
dation to elevated autophagy protein markers, cardiac p62, the
speciﬁc degradation target by autophagolysosome, was evaluated. Our
results showed that p62 protein was signiﬁcantly increased in theAuthors Effect in the heart
Sciarretta et al. [52] Obesity exacerbates cardiac ischemia injury,
prevented by mTORC1 inhibition
He et al. [51] Bcl2 AAA prevents exercise-induced autophagy
activation and protection against high fat diet-induced
metabolic changes
Guo et al. [50] Rapamycin negates high fat diet-induced obesity,
cardiac anomalies and myocardial suppressed autophagy
Xu et al. [12] Akt2 knockout prevents high fat diet-induced obesity,
cardiac injuries andmyocardial autophagic ﬂux disruption
mia)
Li et al. [11] Ossabaw pigs with metabolic syndrome have higher
cardiac output but lower myocardial perfusion.
Cui et al. [21] Caloric restriction recovers myocardial LC3B II/I
without affecting AMPK
Lancel et al. [22] Carbon monoxide-releasing molecule increases
autophagy marker expression, protects high fat
diet-induced mitochondrial dysfunction,
nulliﬁed by 3-methyladenine.
Mellor et al. [55] Fructose increases cardiac superoxide production
and interstitial ﬁbrosis, suppresses cell survival signaling
Xie et al. [53] Metformin rescues myocardial AMPK, autophagy,
and cardiac functions
Xu et al. [54] Beclin1 and Atg16 deﬁciency protect while Beclin1
overexpression exacerbates STZ-induced cardiac injury.
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presence of activated autophagy initiation along with inhibited
autophagosome degradation in hearts from mice with metabolic
syndrome. To further conﬁrm that cardiac autophagosome degradation
is suppressed in high fat diet-induced metabolic syndrome model,
transmission electron microscopy (TEM) was employed for the assess-
ment of autophagosomes and autophagolysosomes. We observed that
the number of double-membrane vacuoles, characteristic of auto-
phagosome, was much higher in cardiac tissues in mice following high
fat diet feeding. However, the number of single-membrane vacuoles,
representing autophagolysosomes, was not signiﬁcantly increased by
high fat diet feeding. The accumulation of double-membrane but not
single-membrane vacuoles indicates that high fat diet-induced meta-
bolic syndrome stimulates autophagy initiation but not accompanied
rise in autophagosome degradation. Our further analysis revealed that
high fat diet feeding-induced inhibition of autophagosome degradation
was probably mediated through downregulation of Rab7, a small
GTPase responsible for fusion between autophagosome and lysosome
[45]. More interestingly, our data revealed that Akt2 knockout effectively
rescued cardiac geometric and functional anomalies, probably through
reversing the suppressed autophagosome degradation in high fat diet-
inducedmetabolic syndrome (Scheme 1) [12]. However, it is still elusive
with regard to how Akt2 regulates Rab7 and autophagic ﬂux in the heart
from mice with metabolic syndrome.
The discrepancies with regard to the effect of metabolic syndrome
onmyocardial autophagymay be attributed to fundamental differences
in experimental models [11,12,21,22]. For example, atherogenic diet
was used to induce metabolic syndrome in the Ossabaw swine [11],
while amousemodel of themetabolic syndromewas induced by chronic
high fat diet feeding [12,21,22]. In murine models of metabolic syn-
drome, the different ﬁndings aboutmyocardial autophagymay be attrib-
uted to differences in diet composition, time course of diet feeding,
animal gender and age [12,21,22]. In the studies inwhichmyocardial au-
tophagy was unaffected by metabolic syndrome, ﬁve-week-old female
C57BL/6 mice were fed 60% high fat diet for 12 weeks by Lancel et al.
[22], and Cui et al. gave 6-week-old male C57 mice male mice 58% high
fat diet for 10 weeks [21]. In contrast, 12-week-old male C57BL/6 mice
were fed 45% high fat diet for 20 weeks in our model of metabolic syn-
drome [12].
The effect of obesity, insulin resistance, and diabetes on cardiac
autophagy has been carefully evaluated by several independent studies
[50–54] (Table 1). He et al. evaluated cardiac autophagy in a mouse
model of obesity induced by 60% high fat diet feeding for 12 weeks
[51]. Their data revealed that the protein level of p62 was dramatically
increased in the heart tissue, without signiﬁcant changes in the ratio
of LC3B-II/LC3B-I in high fat diet-induced obese mice. In another
study, mice were fed high fat diet containing 60% fat for 18 to
20 weeks before the heartwas harvested for autophagy activity analysis
[45]. These obese mice displayed cardiac hypertrophy with preserved
fractional shortening. Interestingly, their data showed that cardiac au-
tophagy was signiﬁcantly suppressed in high fat diet-induced obesity,
as evidenced by decreased LC3B II and increased p62 accumulation
[45]. In addition,myocardial autophagy suppressionwas reported in an-
other mousemodel of obesity induced by 45% high fat diet feeding [50].
In a mouse model of insulin resistance, male C57 mice were fed a high
fructose (60%) diet for 12 weeks prior to the assessment of myocardial
autophagy [55]. Their data revealed that the ratio of LC3B II/LC3B I
was signiﬁcantly increased in the heart under insulin resistance [55].
The authors suggested that autophagy activation might contribute to
cardiac pathology in insulin resistance, although further analysis is re-
quired to support the status of autophagic ﬂux in their mouse model.
Recent studies demonstrated that myocardial autophagy is also altered
in type 1 diabetes mellitus models, contributing to the development of
diabetic cardiomyopathy [53,54]. In OVE26 and streptozotocin (STZ)-
induced type 1 diabetic mice, autophagy was reported to be suppressed
in the diabetic heart [54]. Moreover, autophagy suppression was foundto be protective against diabetic cardiomyopathy, as evidenced by the
attenuation of cardiac injury by Beclin1 and Atg16 deﬁciency but exac-
erbation of cardiac anomalies by Beclin1 overexpression [54]. However,
autophagy suppression was suggested to be detrimental for cardiac
homeostasis maintenance in OVE26 diabetic mice by another indepen-
dent study [53]. Treatment with AMPK activator metformin rescued
AMPK signaling and restoredmyocardial autophagy, resulting in the im-
provement of cardiac function [53]. Although it was claimed that the
cardioprotective effect of metformin against diabetic cardiomyopathy
was through autophagy restoration, it might not be the case given that
metformin may act through other AMPK-mediated pathways. For
example, AMPK can protect mitochondrial biogenesis and promote
ATP-generating pathways [56], both of which may contribute to the
cardioprotective effect of metformin in autophagy-independent
manner.
4. Summary and conclusion
There is a growing need for the understanding of the correlation be-
tweenmetabolic syndrome and cardiac anomalies for themanagement
of metabolic syndrome. Given that metabolic syndrome encompasses a
cluster of cardiovascular risk factors, it is not surprising that patients
with metabolic syndrome are more susceptible to cardiac geometric
and functional anomalies. Accumulating independent clinical studies
have shown that the presence of metabolic syndrome signiﬁcantly en-
hanced morbidity and mortality of cardiac dysfunction in patients all
over the world [23,26,27,29,30]. To better understand the mechanisms
underlyingmetabolic syndrome-associated cardiac anomalies, multiple
experimental models have been established [11,12,21,22]. In the
Ossabaw swine model with metabolic syndrome, myocardial perfusion
was signiﬁcantly decreased with overt inﬂammation, oxidative stress,
mitochondrial dysfunction and interstitial ﬁbrosis [11]. In high fat
diet-inducedmurinemodel of obesity andmetabolic syndrome, cardiac
output and cardiomyocyte contractile function were dramatically
suppressed [12,22]. These models nicely recapitulate human models of
obesity andmetabolic syndrome to be used as a platform for the etiology
and therapeutics of metabolic syndrome.
Over the past years, extensive studies have been focusing on under-
standing the role of myocardial autophagy under various pathological
conditions, including ischemia/reperfusion [18], pressure overload-
induced hypertrophy [19,48,49], and heart failure [20,49]. Although
there is growing interest in the role of autophagy in the maintenance of
cardiac homeostasis under various pathophysiological conditions,
whether and exactly how autophagy is affected in metabolic syndrome-
associated cardiac anomaly still remain elusive.
Up-to-date, the notion of disturbed autophagy in metabolic
syndrome-associated cardiac injury is conceived by conﬂicting experi-
mental data [11,12,21,22]. In the swine model of metabolic syndrome,
myocardium displayed increased protein levels of Atg12–Atg5 along
with decreased ULK1, Beclin1 and the LC3B II/I ratio [11]. In mouse
models of high fat diet-inducedmetabolic syndrome,myocardial autoph-
agy was unaffected although cardiac functionwas suppressed [21,22]. To
the contrary, disturbed cardiac autophagic ﬂux was reported in 45% high
fat diet-induced model of obesity and metabolic syndrome, contributing
to the cardiac geometric and functional anomalies [12]. Such discrepancy
may be attributed to the fundamental differences (diet composition,
animal gender and age) in experimental models [11,12,21,22].
In summary, although the current available information remains
controversial, it is noteworthy that scientists are starting to appreciate
the pivotal role of autophagy in the homeostasis of cardiac geometry
and function under metabolic syndrome. Further studies are warranted
to better understand the inconsistent data published using various
animal models. For example, the contribution of various animal species
and strain to cardiac autophagy under metabolic syndrome remains un-
known. Second, the precise role of diet composition in cardiac autophagy
under metabolic syndrome remains to be determined. Last but not the
230 S.Y. Ren, X. Xu / Biochimica et Biophysica Acta 1852 (2015) 225–231least, it is still unclear whether metabolic syndrome-induced changes in
cardiac autophagy can be inﬂuenced by other factors, including age and
gender. More in depth work is in need to clarify the precise interplay
between cardiac autophagy and cardiac anomalies under metabolic
syndrome. Ultimately, a better understanding of the role of cardiac au-
tophagy inmetabolic-induced cardiac anomalies should shed some lights
towards a better management of cardiac injuries in patients with meta-
bolic syndrome.
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